Dynamic Technology Lab Private LTD Macrogenics Inc Transaction History

Dynamic Technology Lab Private LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$4.48 - $10.11 $84,721 - $191,190	18,911 New	18,911 $182,000
Q1 2023 May 12, 2023	BUY	$4.82 - $7.24 $49,164 - $73,848	10,200 New	10,200 $73,000
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $16,714 - $28,986	-5,553 Reduced 29.45%	13,303 $46,000
Q2 2022 Aug 12, 2022	BUY	$2.25 - $9.99 $42,426 - $188,371	18,856 New	18,856 $56,000
Q1 2022 May 16, 2022	SELL	$8.12 - $16.9 $310,281 - $645,782	-38,212 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $444,079 - $610,714	27,912 Added 270.99%	38,212 $613,000
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $203,321 - $295,610	10,300 New	10,300 $216,000
Q4 2018 Feb 13, 2019	SELL	$11.75 - $21.42 $136,899 - $249,564	-11,651 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$19.26 - $23.46 $224,398 - $273,332	11,651 New	11,651 $250,000
Q2 2018 Aug 14, 2018	SELL	$19.78 - $24.67 $1.17 Million - $1.46 Million	-59,052 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$18.89 - $32.46 $1.12 Million - $1.92 Million	59,052 New	59,052 $1.49 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.